Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 0.66 |
| ▸ | SRC | P12931 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | KIT | P10721 | 1/20 | 0.58 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.58 |
| ▸ | AXL | P30530 | 1/20 | 0.58 |
| ▸ | FLT3 | P36888 | 1/20 | 0.58 |
| ▸ | MST1R | Q04912 | 1/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29529122 | 1.00 | MET (1.00) | METJAK2SRCKDRKIT | |
| SCHEMBL3120131 | 1.00 | MET (1.00) | METJAK2SRCKDRKIT | |
| SCHEMBL15133818 | 1.00 | MET (1.00) | METJAK2SRCKDRKIT | |
| SCHEMBL15779201 | 0.93 | MET (0.88) | METJAK2SRCKDRKIT | |
| SCHEMBL18079539 | 0.86 | MET (0.75) | METJAK2SRCKDRKIT | |
| SCHEMBL14958579 | 0.84 | MET (0.73) | METJAK2SRCKDRKIT | |
| SCHEMBL15779489 | 0.84 | MET (0.71) | METJAK2 | |
| SCHEMBL3123822 | 0.82 | MET (0.69) | METJAK2SRCKDRKIT | |
| SCHEMBL31672489 | 0.82 | MET (0.69) | METJAK2SRCKDRKIT | |
| SCHEMBL3391902 | 0.81 | MET (0.69) | METJAK2SRCKDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108017575-B | Method for synthesizing crizotinib intermediate by using microchannel reactor | 黑龙江鑫创生物科技开发有限公司 | 2021-03-30 | — | — | CN | claimed |
| CN-107417603-B | Preparation method of crizotinib intermediate | 张家港威胜生物医药有限公司 | 2020-08-11 | — | — | CN | claimed |
| CN-110283161-B | Crystal of pyridine substituted 2-aminopyridine protein kinase inhibitor | 正大天晴药业集团股份有限公司 | 2021-09-03 | — | — | CN | disclosed |
| CN-108017575-B | Method for synthesizing crizotinib intermediate by using microchannel reactor | 黑龙江鑫创生物科技开发有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-108017575-B | Method for synthesizing crizotinib intermediate by using microchannel reactor | 黑龙江鑫创生物科技开发有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-112225722-A | Method for preparing crizotinib intermediate by using microchannel reactor | 张家港威胜生物医药有限公司 | 2021-01-15 | — | — | CN | disclosed |
| CN-107417603-B | Preparation method of crizotinib intermediate | 张家港威胜生物医药有限公司 | 2020-08-11 | — | — | CN | disclosed |
| CN-107417603-B | Preparation method of crizotinib intermediate | 张家港威胜生物医药有限公司 | 2020-08-11 | — | — | CN | disclosed |
| EP-3330264-B1 | PYRIDINE SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR CRYSTAL | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2020-05-06 | — | — | EP | disclosed |
| US-10385038-B2 | Pyridine substituted 2-aminopyridine protein kinase inhibitor crystal | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-08-20 | — | — | US | disclosed |
| US-20180244649-A1 | PYRIDINE SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR CRYSTAL | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2018-08-30 | — | — | US | disclosed |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-08-10 | — | — | US | disclosed |
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. | 2006-06-15 | — | — | US | disclosed |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | AGOURON PHARMACEUTICALS, INC. | 2006-03-02 | — | — | US | disclosed |
| WO-2006021884-A2 | ENANTIOMERICALLY PURE AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021881-A2 | PYRAZOLE-SUBSTITUTED AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021886-A1 | AMINOHETEROARYL COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | PFIZER INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | disclosed |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | SUGEN, INC. | 2005-01-13 | — | — | US | disclosed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128724-A1 | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, MAP3K19 | MET 1/4885JAK2 249/4885SRC 145/4885 |
| US-20060046991-A1 | Crizotinib, a c-Met protein kinase inhibitor anticancer agent; 3-[(R)-1-(2,6-dichloro-3-fluoro-phenyl)-ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)-pyridin-2-ylamine is crizotinib | ALK, MET, ERBB2 | MET 2/4885JAK2 192/4885SRC 142/4885 |
| US-20180244649-A1 | PYRIDINE SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR CRYSTAL | MAPKAPK5, ACP1, CSNK1A1 | MET 1148/4885JAK2 249/4885SRC 250/4885 |
| US-10385038-B2 | Pyridine substituted 2-aminopyridine protein kinase inhibitor crystal | MAPKAPK5, ACP1, CSNK1A1 | MET 1148/4885JAK2 249/4885SRC 250/4885 |
| US-20060178374-A1 | Aminoheteroaryl compounds as protein kinase inhibitors | MET, MAP3K15, CDC42BPA | MET 1/4885JAK2 342/4885SRC 90/4885 |
| US-20050009840-A1 | 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer | MET, ERBB2, CDK4 | MET 1/4885JAK2 8/4885SRC 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.